MGNX News and Press, MacroGenics Inc. From 03/25/21

Pieris Pharmaceuticals PIRS +46% on collaboration with Seagen.Houston Wire & Cable Company HWCC +41% on being acquired by OmniCable for $5.30 per share.Cellect Biotechnology APOP +41% on a definitive merger agreement with Quoin Pharmaceuticals.Immutep Limited...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2020 Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call Participants Ev...

MacroGenics (MGNX): FY GAAP EPS of -$2.47 beats by $0.63.Revenue of $104.88M (+63.4% Y/Y) beats by $28.21M.Press Release For further details see: MacroGenics EPS beats by $0.63, beats on revenue

MARGENZA™ approved in December 2020; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for t...

ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its finan...

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica ...

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been...

MGNX has one approved product, and focus is now on its DART platform for developing bispecific antibodies. The early data shows strong potential for flotetuzumab. Their pipeline looks highly diverse and interesting. For further details see: MacroGenics: A Look At The DAR...

We'll take a look at an interesting therapeutic idea involving T-cells and how it's going. For some years now, Amgen has been working on a technology called "BiTE", which stands for "bispecific T-cell engager". It fits into the general "bifunctional molecule" idea that's so popular th...